CD19 and acute lymphoblastic leukemia: The integration of immunotherapeutic agents such as inotuzumab ozogamicin into salvage regimens for R/R ALL has significantly reshaped the therapeutic landscape, particularly in the context of bridging strategies prior to CD19-directed CAR-T cell therapy.